Table 2. R₂ ^* (s⁻¹) at t₀ in each ROI (mean ± standard error).

		t/q	n	GM	GP	SNc	SNr	WM	rPut	cPut
controls	age	1	8	12.46±0.34	25.81±0.59	21.47±0.53	25.79±0.62	17.13±0.32	18.98±0.57	21.67±0.35
(n = 26)		2	7	11.61±0.53	23.73±0.67	20.56±0.52	25.23±0.91	16.25±0.32	18.74±0.70	20.96±0.66
		3	6	12.10±0.28	24.45±1.15	19.66±0.48	23.87±0.81	16.38±0.76	19.41±1.13	21.22±0.80
		4	5	14.03±0.68	24.97±1.32	20.89±0.86	25.45±1.35	17.18±0.52	20.33±0.86	26.17±1.55
	F			4.39	0.6	1.29	1.02	1.25	0.69	5.39
	p			0.0165 *	0.6237	0.3072	0.4063	0.3208	0.5708	0.0074 *
	gender	F	18	12.56±0.36	25.03±0.54	20.91±0.39	25.07±0.43	16.60±0.27	19.67±0.42	22.82±0.71
		M	8	12.19±0.35	24.21±0.82	20.20±0.41	25.28±1.10	17.01±0.49	18.38±0.80	20.92±0.49
	F			0.15	0.51	0.12	0.88	2.46	2.48	0.51
	p			0.702	0.4858	0.7286	0.3612	0.1331	0.1316	0.4827
PD patients	age	1	8	11.65±0.54	25.93±0.72	23.60±0.69	27.14±0.82	15.81±0.49	18.44±0.46	20.34±0.90
(n = 27)		2	5	12.12±0.70	25.87±1.61	22.27±0.61	27.43±2.24	17.25±0.61	18.20±0.51	22.63±1.50
		3	7	12.34±0.62	24.07±0.53	21.11±0.64	25.44±0.89	16.34±0.46	18.40±0.70	22.09±1.07
		4	7	11.54±0.87	25.07±1.19	23.32±0.76	28.26±1.08	15.29±0.55	22.33±1.17	24.91±1.46
	F			0.22	0.07	1.26	1.32	3.08	4.4	1.76
	p			0.8787	0.9753	0.3225	0.3028	0.0575	0.0194 *	0.1944
	gender	F	14	12.15±0.48	24.18±0.44	22.54±0.61	25.54±0.50	16.00±0.36	19.37±0.74	22.23±0.97
		M	13	11.61±0.47	26.33±0.81	22.74±0.48	28.66±0.94	16.17±0.44	19.42±0.71	22.59±0.93
	F			0,01	1,52	0,1	2,12	0,6	0,57	1,54
	p			0,9081	0,2361	0,7576	0,1649	0,4506	0,4625	0,2327
	diseases duration	1	10	11.83±0.53	25.54±0.74	22.64±0.71	26.71±0.51	15.36±0.38	18.65±0.80	22.09±1.32
		2	9	11.40±0.46	25.55±1.02	23.12±0.54	26.48±0.79	16.61±0.37	20.57±0.92	22.86±1.13
		3	8	12.51±0.74	24.44±0.80	22.07±0.77	28.09±1.74	16.39±0.65	18.99±0.82	22.29±0.99
	F			0.17	0.74	0.02	2.02	3.16	1.02	1.37
	p			0.8464	0.4936	0.983	0.1647	0.0696	0.3831	0.282
	Hoehn and Yahr	1	9	11.81±0.58	24.31±0.47	22.23±0.79	26.68±0.50	15.83±0.43	18.78±0.97	21.85±1.39
		2	9	11.54±0.43	26.33±0.70	23.12±0.48	27.78±0.93	16.06±0.41	19.73±0.64	22.32±0.85
		3	9	13.34±0.89	22.85±0.73	21.62±0.98	24.99±1.55	16.66±0.76	19.34±1.62	23.83±1.71
	F			1.98	2.37	0.15	0.43	1.09	0.07	1.01
	p			0.1708	0.1257	0.8614	0.6598	0.3594	0.9285	0.3875
	UPDRS III	1	8	12.40±0.54	25.65±0.88	23.05±0.82	27.07±1.51	16.49±0.97	19.96±0.87	22.89±1.16
		2	10	11.99±0.51	25.63±0.74	22.64±0.65	27.05±0.57	15.79±0.47	18.04±0.29	20.95±1.05
		3	9	11.31±0.67	24.37±0.95	22.25±0.59	27.00±1.13	16.03±0.58	20.39±1.15	23.58±1.16
	F			1.21	0.35	0.03	0.18	0.71	1	0.96
	p			0.3227	0.7077	0.9674	0.8399	0.5077	0.3883	0.4034

n = number of subjects. Age was divided into quartiles (q) (the classes for controls being 42–49, 50–53, 54–67, 68–76; for PD patients 42–49, 50–59, 60–68, 69–78) and disease duration, Hoehn and Yahr stage and UPDRS III in terciles (t) (the classes for disease duration being 1–3, 4–6, 7–21; for HY 1–1.5, 2, 2.5–4; for UPDRS III 4–7.5, 8–12.5, 13–40).

GM = gray matter; GP = Globus Pallidus; SNc = Substantia nigra pars compacta; SNr = Substantia nigra pars reticulata; WM = white matter; rPut = rostral putamen; cPut = caudal putamen.

^*p<0.05; analysis of variance (ANOVA). Post-hoc multiple comparisons (Tukey test) showed in the three cases that the difference was significant between the three first quartiles and the fourth.